Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Recommendation of "Hold" by Analysts

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) have been given a consensus recommendation of "Hold" by the twelve brokerages that are covering the company, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, six have given a hold recommendation and four have issued a buy recommendation on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $61.90.

A number of analysts have recently weighed in on HALO shares. Leerink Partners downgraded Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 target price for the company. in a research report on Tuesday, May 13th. Wells Fargo & Company upped their price objective on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a research report on Wednesday, May 7th. Benchmark cut shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 7th. JPMorgan Chase & Co. increased their price target on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a research report on Monday, April 21st. Finally, HC Wainwright restated a "buy" rating and set a $72.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, May 29th.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock traded up $0.22 during trading hours on Monday, hitting $54.22. The company had a trading volume of 1,730,612 shares, compared to its average volume of 1,756,214. Halozyme Therapeutics has a one year low of $42.01 and a one year high of $70.51. The firm has a 50-day moving average of $55.49 and a 200 day moving average of $56.70. The company has a debt-to-equity ratio of 3.13, a current ratio of 8.39 and a quick ratio of 7.30. The firm has a market cap of $6.68 billion, a PE ratio of 14.42, a PEG ratio of 0.36 and a beta of 1.15.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.98 by $0.13. Halozyme Therapeutics had a net margin of 44.76% and a return on equity of 136.91%. The firm had revenue of $264.86 million for the quarter, compared to analyst estimates of $231.21 million. During the same quarter in the prior year, the business posted $0.79 EPS. The business's revenue was up 35.2% compared to the same quarter last year. On average, sell-side analysts expect that Halozyme Therapeutics will post 4.73 earnings per share for the current year.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $53.73, for a total value of $1,074,600.00. Following the completion of the transaction, the chief executive officer directly owned 733,719 shares in the company, valued at approximately $39,422,721.87. This trade represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jeffrey William Henderson sold 4,497 shares of the business's stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $60.37, for a total value of $271,483.89. Following the sale, the director owned 28,611 shares in the company, valued at approximately $1,727,246.07. This trade represents a 13.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 44,497 shares of company stock valued at $2,405,284 over the last quarter. Company insiders own 2.90% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Bessemer Group Inc. increased its holdings in Halozyme Therapeutics by 62.9% in the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 207 shares during the period. D. E. Shaw & Co. Inc. grew its stake in shares of Halozyme Therapeutics by 171.2% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company's stock valued at $39,750,000 after buying an additional 524,802 shares during the period. Fifth Third Bancorp increased its holdings in shares of Halozyme Therapeutics by 29.4% during the first quarter. Fifth Third Bancorp now owns 10,017 shares of the biopharmaceutical company's stock valued at $639,000 after acquiring an additional 2,276 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Halozyme Therapeutics by 0.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,783,177 shares of the biopharmaceutical company's stock valued at $85,254,000 after buying an additional 9,780 shares in the last quarter. Finally, GAMMA Investing LLC boosted its stake in Halozyme Therapeutics by 199.0% during the 1st quarter. GAMMA Investing LLC now owns 2,802 shares of the biopharmaceutical company's stock valued at $179,000 after purchasing an additional 1,865 shares during the last quarter. Institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.